Background--Attenuated cardiac vagal activity is associated with ventricular arrhythmogenesis and related mortality in patients with chronic heart failure. Our recent study has shown that expression of N-type Ca 2+ channel a-subunits (Ca v 2.2-a) and N-type Ca 2+ currents are reduced in intracardiac ganglion neurons from rats with chronic heart failure. Rat intracardiac ganglia are divided into the atrioventricular ganglion (AVG) and sinoatrial ganglion. Ventricular myocardium receives projection of neuronal terminals only from the AVG. In this study we tested whether a decrease in N-type Ca 2+ channels in AVG neurons contributes to ventricular arrhythmogenesis.
M alignant ventricular arrhythmia including ventricular tachycardia (VT) and ventricular fibrillation (VF) is a common complication in chronic heart failure (CHF) and accounts for nearly 50% to 60% of mortality in patients with CHF. [1] [2] [3] [4] [5] [6] Cardiac autonomic dysfunction is a major feature of CHF, characterized by a sustained increase of sympathetic tone and withdrawal of cardiac vagal activity. [7] [8] [9] Much evidence has shown that this autonomic imbalance leads to arrhythmogenesis and is associated with the high mortality of CHF. 2, 10, 11 The role of sympathetic hyperactivation in CHF is highlighted by a blockade of the sympathetic nervous system (b-adrenergic receptor blockers) as the key approach to the current therapy of CHF. [12] [13] [14] However, such pharmacological treatment is not ideal because the ability of b-adrenergic receptor blockers to affect cardiac vagal activity is limited, 15 and survival rates even when b-blockers are used are lower in CHF patients with depressed cardiac vagal activity than in CHF patients with normal cardiac vagal activity. 16 Although modulation of cardiac vagal activation as a potential therapy has received only limited attention, direct cardiac vagal nerve stimulation has been found to suppress ventricular tachyarrhythmia and to improve survival rates in CHF. [17] [18] [19] Therefore, exploring the mechanism(s) responsible for the impairment of cardiac vagal function can provide a new therapeutic strategy for eliminating ventricular tachyarrhythmia and reducing related mortality. Cardiac vagal preganglionic fibers originate within the central nervous system at the brainstem (nucleus ambiguus, nucleus tractus solitarius, and dorsal motor nucleus). The vagal preganglionic efferent extends to the intracardiac ganglia, located in cardiac fat pads, to form synapses with intracardiac ganglion neurons. 20 Intracardiac ganglion neurons provide local neural coordination independent of high brain centers. 21 Acetylcholine released from cardiac vagal efferent nerve terminals regulates cardiac function through binding to muscarinic acetylcholine receptors. It is known that Ca 2+ influx through voltage-gated Ca 2+ channels is a key trigger for acetylcholine release from nerve terminals. 22 Our recent study demonstrates that expression of N-type Ca 2+ channel a-subunit (Ca v 2.2-a) mRNA and protein is decreased in intracardiac ganglion neurons from CHF rats. 23 Rat intracardiac ganglia are divided into the sinoatrial ganglion and atrioventricular ganglion (AVG), 24 and the ventricle receives projection of nerve terminals only from the AVG. 25 In the present study, therefore, we used lentiviral Ca v 2.2-a shRNA to knock down expression of Ca v 2.2-a mRNA and protein in AVG neurons and tested the contribution of reduced N-type Ca 2+ channels in AVG neurons to ventricular arrhythmogenesis in conscious and anesthetized rats.
Methods
All data, analytic methods, and study materials have been provided within the article.
Experimental Animals
Male Sprague-Dawley rats (9-11 weeks of age) were used in this study. They were housed 2 per cage under controlled temperature and humidity and a 12:12-hour dark-light cycle and were provided water and rat chow ad libitum. All experimental procedures were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Microinjection of Lentiviral Ca v 2.2-a shRNA into the AVG
Under surgical anesthesia (2% isoflurane) and mechanical ventilation, rats were kept in right lateral recumbent position. A left posterolateral thoracotomy was done through the third left intercostal space on the back, and the left lung was moved aside to expose the AVG. There was a white color epicardial adipose pad at the junction of the inferior pulmonary veins and left atrium, which served as a marker for the virus microinjection because the AVG is located in this pad ( Figure 1A ). The heart beating was very weak at the junction of the inferior pulmonary veins and left atrium when the AVG was exposed under the left posterolateral thoracotomy, which ensured the success of the virus microinjection into the AVG. Under the microscope, lentiviral rat Ca v 2.2-a shRNA with phosphorylated green fluorescent protein (pGFP) or shRNA scramble control (2 lL, 2.0910 7 pfu/mL, TL713159V and TR30021V, OriGene Technologies, Rockville, MD) was microinjected into the epicardial adipose pad by a glass micropipette connected to a WPI Nanoliter 2000 microinjector ( Figure 1A ). Scrambled shRNA was used to assess possible toxicity of lentivirus. After transfection, the chest was closed, and experiments were performed 1 week later to guarantee degradation of existing Ca v 2.2-a protein.
Efficacy of Lentivirus Infection
Efficacy of the lentivirus infection was assessed by immunofluorescence staining. Briefly, isolated AVGs from 3 rats with transfection of lentiviral rat Ca v 2.2-a shRNA with pGFP were postfixed in 4% paraformaldehyde, followed by soaking of AVGs in 30% sucrose for 12 hours at 4°C for cryostat protection. AVGs were cut into 10-lm-thick sections at À20°C and then mounted on precoated glass slides. AVG sections were incubated with 10% donkey serum for 1 hour, followed by incubation with goat anti-choline acetyltransferase antibody (a cholinergic neuronal marker; EMD Millipore, Billerica, MA) overnight at 4°C. Then AVG sections were incubated with fluorescence-conjugated secondary antibody (Invitrogen, Carlsbad, CA) for 1 hour at room temperature. AVG sections were examined under a Leica (Wetzlar, Germany) fluorescent microscope with corresponding filters for choline acetyltransferase (red color) and pGFP (green What Are the Clinical Implications?
• Withdrawal of cardiac vagal activity might be involved in occurrence of fatal ventricular arrhythmias in the chronic heart failure state.
• Improvement of the ventricular vagal activity might be an effective therapeutic strategy to limit malignant ventricular arrhythmias and cardiac sudden death in chronic heart failure.
color). The imaging was captured by a digital camera system. Figure 1B shows that microinjection of lentiviral rat Ca v 2.2-a shRNA with pGFP into the AVG induced pGFP expression in almost all choline acetyltransferase-positive AVG neurons (n=3 rats), confirming the efficacy of virus infection and proper microinjection into the AVG.
Labeling and Isolation of AVG Neurons
Although ventricular myocardium receives projection of nerve terminals only from the AVG, 25 it is possible that the AVG also innervates other parts of the heart. Therefore, we used a transported flurescent dye (red color DiI) to retrograde-label cardiac vagal neurons projecting to the ventricular myocardium. Rats were anesthetized with 2% isofluorane and artificially ventilated. After a left thoracotomy was performed to expose the heart, 8 injections (2 lL DiI for each injection) were made subepicardially into the left ventricular myocardium using a glass micropipette connected to a WPI (Sarasota, FL) Nanoliter 2000 microinjector. 23 The surgical incision was closed, and terminal experiments were performed at least 3 days after labeling surgery because we found that 3 days are needed for dye diffusion to the neurons. 23 DiI-labeled AVG neurons (ventricular vagal neurons) were used to perform single-cell real-time reversetranscription (RT) polymerase chain reaction (PCR) and whole-cell patch-clamp recording.
ECG Transmitter Implantation and Electrocardiographic Recording
Each rat was anesthetized with 2% isoflurane (Butler Schein Animal Health, Dublin, OH). The skin was first shaved and sterilized. After laparotomy was performed at the linea alba (abdomen), the radiotelemetry ECG transmitter 26 and QTc max are the maximum QT interval and the maximum QTc interval; QT min and QTc min are the minimum QT interval and the minimum QTc interval. 27 The T-peak to T-end interval (Tpe),
another marker of transmural dispersion of the ventricular repolarization, was calculated from ECG recordings to serve as an ECG marker of ventricular arrhythmia. 28 
Measurement of Susceptibility to Ventricular Arrhythmias
Susceptibility to ventricular arrhythmias was measured as described previously. 26 On the day of the terminal experiment
(1 day after radiotelemetry ECG recording), each rat was anesthetized (800 mg/kg urethane combined with 40 mg/kg a-chloralose, intraperitoneally). The animal's trachea was cannulated to facilitate mechanical respiration. The animal's body temperature was maintained at 37°C with an Animal Temperature Controller (ATC 1000; World Precision Instruments, Sarasota, FL). Surface lead-II ECG was recorded using subcutaneous electrodes connected to a biological amplifier (AD Instruments, Colorado Springs, CO). A left thoracotomy was then performed in the fourth intercostal space. After the heart was visualized, the pericardium was carefully removed. A bipolar platinum stimulating electrode was placed on the right ventricle outflow tract for programmed electrical stimulation (PES). The PES was performed by a programmed electrical stimulator (Digital Pulse Generator 1831, WPI) and an isolator (A320R Isostim Stimulator, WPI). The pulse current output was set to a twice capture threshold and a 2-millisecond pulse width. To determine the ventricular effective refractory period, a train of 8 stimuli (89S1) at a 120-millisecond cycle length was applied, followed by an extra stimulus (S2). Starting at 90 milliseconds, the S1 to S2 interval was reduced in steps of 2 milliseconds until the ventricular effective refractory period was identified. Based on the ventricular effective refractory period, a programmed stimulation protocol combined by single (S2), double (S3), or triple extra stimulus (S4) after a train of 8 stimuli (89S1) was designed to induce ventricular tachyarrhythmias. The end point of ventricular pacing was induction of ventricular tachyarrhythmia. Ventricular tachyarrhythmia was considered noninducible when the PES induced either no ventricular premature beats or self-terminated ventricular premature beats <6. Ventricular tachyarrhythmia was considered as nonsustained when it lasted ≤15 beats and sustained when it lasted >15 beats before spontaneously terminating. Inducibility of ventricular tachyarrhythmia was quantified by a quotient of ventricular arrhythmic scores: 0, noninducible preparations; 1, nonsustained tachyarrhythmias induced with 3 extra stimuli; 2, sustained tachyarrhythmias induced with 3 extra stimuli; 3, nonsustained tachyarrhythmias induced with 2 extra stimuli; 4, sustained tachyarrhythmias induced with 2 extra stimuli; 5, nonsustained tachyarrhythmias induced with 1 extra stimulus; 6, sustained tachyarrhythmias induced with 1 extra stimulus; 7, tachyarrhythmias induced during a train of 8 stimuli (89S 1 ) at a basic cycle length of 120 milliseconds; 8, the heart stopped before the PES.
Measurement of Hemodynamics and Vagal Control of Ventricular Function
After the susceptibility to ventricular arrhythmias had been detected, the left femoral artery was cannulated with a polyethylene-50 catheter for measurement of blood pressure and heart rate. 26 
Isolation of AVG Neurons and Single-Cell RealTime RT-PCR
After in-vivo experiments were performed, the AVG, located in a white epicardial adipose pad at the junction of inferior pulmonary veins and left atrium, was exposed. AVG neurons were isolated by a 2-step enzymatic digestion protocol, as described previously. 23 In voltage-clamp experiments, resistance of the patch pipette was 4 to 6 MΩ when the pipette was filled with the following solution (in mmol/L): 120 CsCl, 1 CaCl 2 , 40 HEPES, 11 EGTA, 4 MgATP, 0.3 Tris-GTP, 14 creatine phosphate, and 0.1 leupeptin (pH 7.3; 305 mosmol/kg). The extracellular solution consisted of (in mmol/L): 140 TEA-Cl, 5 BaCl 2 , 1 MgCl 2 , 10 HEPES, 0.001 TTX, 2 4-AP, and 10 glucose (pH 7.4; 310 mosmol/kg). Series resistance of 5 to 13 MO was electronically compensated at 30% to 80%. The junction potential was calculated to be +7.9 mV using the P-clamp 10.2 program (Molecular Devices, Sunnyvale, CA), and all values of membrane potential given throughout were corrected using this value. Current traces were sampled at 10 kHz and filtered at 5 kHz. The holding potential was À80 mV, and current-voltage relationships were elicited by 5-mV step increments to potentials between À60 and 60 mV for 500 milliseconds. N-type Ca 2+ currents were obtained by subtracting the Ca 2+ currents under treatment with xconotoxin GVIA from total Ca 2+ currents. Based on the previous study, the concentration of x-conotoxin GVIA (1 lmol/L, a specific N-type Ca 2+ channel blocker) used in the present study is a saturating concentration for inhibiting N-type Ca 2+ channels. 23, 36 Peak currents were measured for each test potential, and current density was calculated by dividing peak current by cell membrane capacitance. In current-clamp experiments action potentials were elicited by a ramp current injection of 0 to 100 pA, and frequency of action potentials was measured in a 1-second current clamp. The patch-pipette solution was composed of (in mmol/L): 105 K-aspartate, 20 KCl, 1 CaCl 2 , 5 MgATP, 10 HEPES, 10 EGTA, and 25 glucose (pH 7.2; 320 mosmol/kg). The bath solution was composed of (in mmol/L): 140 NaCl, 5.4 KCl, 0.5 MgCl 2 , 2.5 CaCl 2 , 5.5 HEPES, 11 glucose, and 10 sucrose (pH 7.4; 330 mosmol/kg). Junction potential was calculated to be +12.3 mV, and membrane potential was corrected using this value. The P-clamp 10.2 program (Molecular Devices, Sunnyvale, CA) was used for data acquisition and analysis. All experiments were done at room temperature (22-24°C).
Statistical Analysis
All data are presented as meansAESEM. SigmaPlot 12 (Systat Software, Chicago, IL) was used for data analysis. We analyzed the normal distribution of the data using the Kolmogorov-Smirnov test and found that statistical analyses for the normal distribution of the data are passed in all parameters. Statistical significance was determined by a Fisher exact test for incidence of ventricular arrhythmias because some cells have fewer than 5 expected observations. Statistical significance was determined by 1-way ANOVA with post hoc Dunnett test against the sham group for most of the parameters. Statistical significance in some experiments was determined by 1-way repeated-measures ANOVA with post hoc Dunnett test against the sham group. Statistical significance was determined by paired t-test for comparison between before and after treatments. Because of the heterogeneity among the dissociated neurons from 1 animal, we used neuron numbers to do statistical analyses for Ca v 2.2-a mRNA, N-type Ca 2+ currents, and action potentials.
Statistical significance was accepted when P<0.05. Figure 1C and 1D) . However, shRNA scramble control had no effect on expression of Ca v 2.2-a mRNA and protein in AVG neurons ( Figure 1C and 1D) . currents in ventricular vagal neurons (Figure 3Aa through Ac). Ca v 2.2-a shRNA also reduced frequency of action potentials (a parameter of the cell excitability) in ventricular vagal neurons (Figure 3Ba and Bb). However, there were no significant differences in resting membrane potential, input resistance, and cell membrane capacitance in ventricular vagal neurons from all groups of rats ( Table 2) .
Results

Efficacy of Lentiviral Ca v 2.2-a shRNA
Ca v 2.2-a shRNA Attenuated Vagal Control of the Ventricle
We hypothesized that attenuated ventricular vagal activity through in vivo transfection of Ca v 2.2-a shRNA into AVG neurons could be linked to ventricular arrhythmogenesis. Activation of the vagal efferent nerve results in a negative inotropic effect in the ventricle, which serves as an index of ventricular vagal function. 37 Ca v 2.2-a shRNA transfection into AVG neurons significantly blunted changes of the LVSP and maximum rate of left ventricular pressure rise in response to vagal efferent nerve stimulation, compared with sham rats (Figure 4 ). However, shRNA scramble control did not show any effect on vagal control of the ventricle. Additionally, transfection of Ca v 2.2-a shRNA into AVG neurons increased basal LVSP with the absence of heart-rate changes (Table 3) , which further confirmed that transfection of Ca v 2.2-a shRNA into AVG neurons only blunted ventricular vagal activity and did not affect sinoatrial vagal activity. Figure 5 shows the effect of Ca v 2.2-a shRNA on the susceptibility to ventricular arrhythmias in anesthetized rats ( Figure 5 ). A PES protocol was performed to induce ventricular arrhythmias in anesthetized rats, and an inducibility quotient was used to evaluate the susceptibility to ventricular arrhythmias. Ventricular arrhythmias were not induced by S 1 S 2 S 3 S 4 programmed stimulation, and the inducibility quotient of ventricular arrhythmias was 0 in sham rats ( Figure 5 ). After in vivo transfection of Ca v 2.2-a shRNA into AVG neurons, 83.3% (5/6) of the rats had PESinduced ventricular arrhythmias, and the inducibility quotient of ventricular arrhythmias was 1.97AE0.49 ( Figure 5 ; P<0.05 versus sham rats). However, there was nonoccurrence of PES-induced ventricular arrhythmias in rats with transfection of shRNA scramble control ( Figure 5 ).
Effect of Ca v 2.2-a shRNA on Susceptibility to Ventricular Arrhythmias in Anesthetized Rats
Effect of Ca v 2.2-a shRNA on Spontaneous Ventricular Arrhythmias and ECG Parameters in Conscious Rats
Spontaneous ventricular arrhythmias and ECG parameters in conscious rats were monitored by radiotelemetry ECG recording (Figures 6 and 7) . There was nonoccurrence of spontaneous ventricular arrhythmias in sham rats (0/6 of the rats, Figure 6 ). After in vivo transfection of Ca v 2.2-a shRNA into AVG neurons, 83.3% (5/6) of the rats had PVCs, and the number of spontaneous PVCs was 10AE4 beats/h (Figure 6 ; P<0.05 versus sham rats). In vivo transfection of shRNA scramble control into AVG neurons did not induce spontaneous ventricular arrhythmias ( Figure 6 ). Simultaneously, in vivo transfection of Ca v 2.2-a shRNA into AVG neurons increased the QT interval, QTc interval, QT d , QTc d , and Tpe, compared with sham rats or before treatment with Ca v 2.2-a shRNA (Figure 7 ; P<0.05). However, scrambled shRNA did not affect these arrhythmia-related ECG parameters ( Figure 7) . 
Discussion
In the present study we tested the influence of reduced Ntype Ca Like a natural yin-yang pair, the sympathetic and parasympathetic nervous systems play an important regulatory role in heart functions including cardiac electrophysiology and cardiac muscle contraction. In particular, a sustained increase of sympathetic activity and a marked decrease of parasympathetic tone are used as distinctive hallmarks of CHF. [7] [8] [9] Thus far, most of the studies used the analysis of heart-rate variability and arterial baroreflex sensitivity to evaluate cardiac sympathetic and parasympathetic autonomic activity in physiological and pathophysiological conditions. 38 Although traditional teaching has stated that cardiac vagal postganglionic nerves regulate the heart through slowing sinus rate and atrioventricular conduction, with little influence on ventricles, and ventricular vagal innervation is considered to be sparse, 18, 39 newer histological techniques have challenged this traditional principle and affirmed dense vagal innervation in the ventricle from all species. 18, [40] [41] [42] [43] Recent studies have demonstrated that functionally significant parasympathetic control of ventricular contractile function and excitability exists in rats, and vagal preganglionic neurons of the dorsal motor nucleus contribute to the vagal control of ventricular contractility and excitability. 44, 45 Therefore, directly examining ventricular vagal activity is very useful to assess the vagal modulation of ventricular arrhythmia and contractile dysfunction. Cardiac vagal postganglionic neurons are located in the intracardiac ganglia. Rat intracardiac ganglia are divided into the sinoatrial ganglion and the AVG. 24 The ventricular myocardium only receives the projection of nerve terminals from the AVG. 25 In our present study we measured the left ventricular pressure and vagal efferent nerve stimulationinduced negative inotropic response in the left ventricle; the latter serves as an index of ventricular vagal activity. 37 In vivo transfection of Ca v 2.2-a shRNA into AVG neurons increased basal LVSP with the absence of heart-rate changes in anesthetized rats ( Recent studies have also found that the parasympathetic activation induced by vagal nerve stimulation prevents fatal ventricular arrhythmias and improves survival rates in animal CHF models. [17] [18] [19] However, there is no direct evidence to clarify the role of decreased parasympathetic activity in ventricular arrhythmogenesis and how decreased parasympathetic activity links to ventricular arrhythmogenesis in CHF due to the coexistence of multiple factors in the CHF state (such as sympathetic overactivation, ventricular morphological changes, and others). In the present study in vivo transfection of Ca v 2.2-a shRNA into AVG neurons decreased expression and ion currents of N-type Ca 2+ channels and cell excitability in ventricular vagal neurons (Figures 1 and 3 ) and blunted the ventricular vagal activity (Figure 4 ) as well as increased the susceptibility to ventricular arrhythmias of anesthetized rats ( Figure 5 ). More importantly, ECG data obtained from radiotelemetry recording demonstrated that in vivo transfection of Ca v 2.2-a shRNA into AVG neurons not only increased the QT interval, QTc interval, QTd, QTcd, and Tpe but also induced a spontaneous ventricular tachyarrhythmia in conscious rats (Figures 6 and 7) . It has been found that prolongation of the QT and QTc intervals, increase of the QTd and QTcd (a marker of spatial heterogeneity of ventricular repolarization), and prolonged Tpe (a marker of transmural dispersion of ventricular repolarization) are associated with increased risk of malignant ventricular arrhythmias and sudden cardiac death. [49] [50] [51] [52] The results in the present study provide direct evidence that blunted ventricular vagal activity increases the susceptibility to ventricular arrhythmias and induces ventricular arrhythmias.
Our recent study has demonstrated that the occurrence of lethal ventricular arrhythmias is accompanied by reduced Ntype Ca 2+ currents in AVG neurons and blunted ventricular vagal activity in coronary artery ligation-induced CHF rats. 26 In the present study, although in vivo transfection of Ca v 2.2-a shRNA into AVG neurons significantly decreased expression and ion currents of N-type Ca 2+ channels in ventricular vagal neurons and blunted ventricular vagal activity, it merely induced spontaneous PVCs but not lethal ventricular arrhythmias such as VT/VF in conscious rats. In general, the combination of proarrhythmic substrates and triggers is necessary to initiate lethal ventricular arrhythmias under the CHF state. Besides blunted ventricular vagal activity, therefore, other determinants of ventricular arrhythmias such as myocardial infarction and sympathetic overactivation are the prerequisite factors for fatal ventricular arrhythmogenesis. Because of the limitation of small AVG samples (1-2 mg wet weight), we could not detect expression of Ca v 2.2-a mRNA and protein using regular real-time RT-PCR and Western blot analyses and instead employed single-cell realtime RT-PCR and modified reverse-phase protein microarray. Before performing reverse-phase protein microarray, therefore, we used the rat brain as a Ca v 2.2-a-positive sample and the gastrocnemius muscle as a Ca v 2.2-a-negative sample to evaluate target specificity of Ca v 2.2-a antibody (Figure 2) . Additionally, we do realize a possible limitation of small animals for extrapolating the findings obtained in this study to humans, although the rat has contributed markedly to assessment of the pathophysiology and treatment of CHF and to the advancement of clinical care. [53] [54] [55] Large animals could be an appropriate alternative for translational experiments. However, the lack of genetic and molecular tools (including a viral vector carrying large-animal genes or shRNAs, and antibodies for large animals) does not allow us to use large animals for these experiments in this study. A hallmark of CHF, withdrawal of cardiac vagal activity, is associated with ventricular arrhythmogenesis, yet sites and mechanisms involved in abnormal cardiac vagal activity remain unclear. Although our recent study demonstrates that the decrease of N-type Ca 2+ currents in AVG neurons correlates with occurrence of ventricular arrhythmias in CHF rats, 26 we could not clarify whether the occurrence of ventricular arrhythmia in CHF rats is totally or partially due to neuronal remodeling of AVG neurons. This is because these experiments were performed with both coronary artery ligation-induced CHF and other determinants of ventricular arrhythmias, such as CHF-induced changes of ventricular myocytes themselves. Our current study decreases N-type Ca 2+ channels in AVG neurons and ventricular vagal activity in sham rats without changing the above factors. Therefore, this current study provides direct evidence that blunted ventricular vagal activity is a determinant of ventricular arrhythmogenesis to increase the susceptibility to ventricular arrhythmias and initiate ventricular arrhythmias as a trigger. Improvement of the ventricular vagal activity might be an effective therapeutic strategy to limit malignant ventricular arrhythmias and cardiac sudden death in patients with CHF.
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